Hematology Times
|
Pediatric HematologyRisk of hematologic, other cancers after CT scans
Patient undergoing a CT scan
Credit: Angela Mary Butler A large, population-based study has provided additional insight into the risk of hematologic and solid tumor malignancies associated with CT scans. Previous research has suggested CT scans pose cancer risks, particularly following exposures in childhood. However, most studies have estimated risks indirectly, and some radiation experts have questioned the validity of these estimates. To provide more definitive data, John D. Mathews, MD, PhD, of the University of Melbourne in Australia . . . [Read Article] Pioneer of ALL treatment dies
Emil Frei III, MD
Credit: Steve Gilbert The “father of combination chemotherapy,” Emil “Tom” Frei III, MD, has died at the age of 89. His work helped bring about the first complete cures for pediatric leukemia patients and led to more effective treatments for a number of adult malignancies, including non-Hodgkin lymphoma, breast cancer, and osteogenic sarcoma. Dr Frei became known as the “father of combination chemotherapy” for demonstrating in the 1950s and 1960s that treatment with . . . [Read Article] US has more than 200 hematology drugs in the pipeline
Worker prepares pills
for a clinical trial Credit: Esther Dyson US pharmaceutical companies are currently developing more than 200 drugs for the treatment of hematologic disorders, according to a new report. But only a few of those drugs have reached the final stages of development, and it is unclear how many will ultimately gain FDA approval. The report, created by Pharmaceutical Research and Manufacturers of America (PhRMA), lists 241 drugs that are being evaluated in clinical trials or are under review by the FDA. [Read Article] Are most kids readmitted to hospital after HSCT?
Preparation for HSCT
Credit: Chad McNeeley Results of a record review indicate that hospital readmission may be common for children who undergo hematopoietic stem cell transplants (HSCTs). Nearly two-thirds of the children included in this review returned to the hospital within 6 months of their HSCT—to receive treatment for unexplained fevers, infections, and other problems. Furthermore, children who received donor stem cells were twice as likely to be readmitted as children who underwent autologous HSCT. [Read Article] Pathway may be vital for TEL-AML1 leukemia
Posters at AACR 2013
Credit: AACR/Todd Buchanan Preclinical research has revealed a signaling pathway that appears to be important for the maintenance of TEL-AML1 leukemia. The researchers showed that TEL-AML1 regulates STAT3 by increasing the activity of RAC1. And this activity is necessary for the expression of MYC. Furthermore, both TEL-AML1-positive human cell lines and primary human leukemia samples were highly sensitive to the STAT3 inhibitor S3I-201. Maurizio Mangolini, of the UCL Institute of Child Health in London . . . [Read Article] |
|